Navigating the regulatory landscape for clinical trials can be complex, especially when determining whether your research requires an Investigational New Drug (IND) application. This critical decision affects timelines, costs, and compliance obligations for pharmaceutical companies, biotechnology firms, and academic researchers conducting human studies.
Understanding who must submit an IND application and when this requirement applies is essential for any organization planning to test investigational drugs, biologics, or medical devices in human subjects. The FDA’s IND regulations serve as a gateway to clinical research, ensuring patient safety while enabling innovation in medical treatments.
What Is an IND Application and Why Is It Required?
An IND application is a regulatory submission to the FDA that allows sponsors to ship and administer investigational drugs to human subjects in clinical trials. The FDA requires IND applications to ensure investigational products meet safety standards before human testing begins, protecting participants while enabling medical research to advance.
The IND serves multiple critical functions in the drug development process. It provides the FDA with comprehensive information about the investigational product, including manufacturing details, preclinical safety data, and proposed clinical protocols. This submission establishes a legal framework for conducting clinical research under FDA oversight.
Beyond regulatory compliance, the IND application demonstrates that sponsors have conducted adequate preclinical research and established appropriate safety monitoring procedures. The FDA reviews each submission within 30 days, during which time the agency may place the study on clinical hold if safety concerns arise or additional information is needed.
Which Companies Must Submit IND Applications to the FDA?
Any company or organization planning to conduct clinical trials with investigational drugs, biologics, or certain medical devices in the United States must submit an IND application. This requirement applies to pharmaceutical companies, biotechnology firms, medical device manufacturers, and contract research organizations serving as sponsors.
The sponsor designation determines IND responsibility. The sponsor is the individual or organization that initiates, conducts, and takes responsibility for a clinical investigation. This can be the product manufacturer, a clinical research organization acting on behalf of the manufacturer, or an independent researcher.
International companies conducting studies in the United States must also comply with IND requirements, even if their products are already approved in other countries. The FDA maintains jurisdiction over all clinical research conducted within U.S. borders, regardless of the sponsor’s location or the product’s regulatory status elsewhere.
What’s the Difference Between Commercial and Research IND Applications?
Commercial INDs are submitted by pharmaceutical or biotechnology companies developing products for eventual marketing approval, while research INDs are filed by academic investigators studying investigational products for scientific purposes without commercial intent. The key distinction lies in the sponsor’s ultimate goal and the scope of development activities.
Commercial IND sponsors typically conduct larger, multi-phase clinical programs designed to generate data for New Drug Applications or Biologics License Applications. These submissions often involve significant financial investment and comprehensive development plans spanning several years.
Research INDs, conversely, usually support smaller-scale academic studies focused on specific scientific questions. These investigations may explore new indications for existing drugs, investigate mechanisms of action, or evaluate novel therapeutic approaches. Research IND holders generally have more limited resources and narrower study objectives compared to commercial sponsors.
When Do Academic Researchers Need to File an IND?
Academic researchers must file an IND when their studies involve investigational drugs that are not commercially available, use approved drugs in ways that significantly differ from labeled indications, or combine multiple investigational products. The FDA requires IND submissions regardless of whether the research is conducted for academic or commercial purposes.
Several specific scenarios trigger IND requirements for academic investigators. These include studying unapproved drugs or biologics, using approved products at doses significantly higher than labeled recommendations, or investigating new routes of administration. Additionally, studies involving drug combinations not previously tested together typically require IND submissions.
Academic medical centers often have institutional review processes to help researchers determine IND requirements. However, the ultimate responsibility for compliance rests with the principal investigator serving as the sponsor. Many universities provide regulatory support services to assist faculty with these complex determinations.
How Do You Determine Whether Your Study Requires an IND Submission?
Determining IND requirements involves evaluating whether your study meets FDA exemption criteria or falls under investigational product regulations. Studies using approved drugs according to their labeled indications and meeting specific FDA exemption requirements may not need IND submissions, while research involving unapproved products or significant deviations from approved uses typically requires regulatory authorization.
The FDA provides specific exemption criteria in 21 CFR 312.2(b) that outline when IND applications are not required. These exemptions apply to studies using lawfully marketed drugs, conducted by qualified investigators, and not intended to support new drug applications. The research must also not involve routes of administration, dosages, or patient populations that significantly increase risk.
Key factors in this determination include the regulatory status of the investigational product, proposed dosing regimens, study population characteristics, and intended use of the research data. Complex cases may require consultation with regulatory experts or direct communication with the FDA through pre-IND meetings to clarify requirements.
How We Help with IND Applications
At Starodub, we provide comprehensive support for IND applications across all phases of clinical development. Our regulatory experts help determine IND requirements, prepare compliant submissions, and navigate FDA interactions throughout the clinical trial process.
Our IND application services include:
- IND requirement assessments and regulatory pathway guidance
- Complete IND dossier preparation and submission management
- FDA correspondence handling and clinical hold resolution
- Protocol development and regulatory compliance consulting
- Post-submission support and amendment preparation
Ready to move forward with your clinical trial application? Contact our regulatory team today to discuss your IND requirements and develop a strategic approach for your clinical development program.
